Population
Transgenic mouse model expressing the apical hypertrophic cardiomyopathy-causing mutation ACTC E99K at 50%…
Comparison
ACTC E99K mutation vs Nontransgenic littermates and control human…
Design
Preclinical
Follow-up
up to 38 weeks in mice
Authors
Loading...
Suggests Ca2+ sensitization drives apical hypertrophy and HF; hypothesis-generating for ACTC cardiomyopathy and requires human validation.
The ACTC E99K mutation increases myofibrillar Ca(2+) sensitivity, driving the development of apical hypertrophy, sudden cardiac death, and heart failure.
Song et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: